Literature DB >> 23669731

Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG.

Lidija Kitanovski1, Silvester Kopriva, Marko Pokorn, Majda B Dolničar, Vladan Rajić, Milica Stefanović, Janez Jazbec.   

Abstract

BACKGROUND: The clinical manifestations of human metapneumovirus (hMPV) infection resemble those of respiratory syncytial virus with the most severe disease occurring in infants, the elderly, chronically ill, and immunocompromised hosts. OBSERVATION: We present a case of a 2-year-old girl undergoing intensive chemotherapy for Burkitt lymphoma who developed severe hMPV pneumonia. Rapid and complete recovery was observed after treatment with oral ribavirin and intravenous immunoglobulin.
CONCLUSION: As hMPV can cause severe pneumonia in immunocompromised patients and due to the reports of effective treatment with ribavirin, clinical studies to elucidate the role of ribavirin in treatment of hMPV pneumonia may be needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669731     DOI: 10.1097/MPH.0b013e3182915d2d

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  16 in total

Review 1.  New Approaches for Immunization and Therapy against Human Metapneumovirus.

Authors:  Sherry C Wen; John V Williams
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

2.  HRA2pl peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation.

Authors:  Verónica A Márquez-Escobar; Rocío Tirado-Mendoza; Daniel E Noyola; Abel Gutiérrez-Ortega; Ángel G Alpuche-Solís
Journal:  Planta       Date:  2015-04-01       Impact factor: 4.116

Review 3.  How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

Review 4.  Severe Respiratory Viral Infections: New Evidence and Changing Paradigms.

Authors:  James M Walter; Richard G Wunderink
Journal:  Infect Dis Clin North Am       Date:  2017-07-05       Impact factor: 5.982

Review 5.  Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.

Authors:  Dimpy P Shah; Pankil K Shah; Jacques M Azzi; Firas El Chaer; Roy F Chemaly
Journal:  Cancer Lett       Date:  2016-05-31       Impact factor: 8.679

6.  Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children.

Authors:  Helen Y Chu; Christian Renaud; Elle Ficken; Blythe Thomson; Jane Kuypers; Janet A Englund
Journal:  J Pediatric Infect Dis Soc       Date:  2014-10-21       Impact factor: 3.164

7.  Human metapneumovirus in the preterm neonate: current perspectives.

Authors:  Nathalie L Maitre; John V Williams
Journal:  Res Rep Neonatol       Date:  2016-07-28

Review 8.  Prophylactic and therapeutic approaches for human metapneumovirus.

Authors:  Prashant Kumar; Mansi Srivastava
Journal:  Virusdisease       Date:  2018-10-20

Review 9.  Interferon-Mediated Response to Human Metapneumovirus Infection.

Authors:  Ifeanyi K Uche; Antonieta Guerrero-Plata
Journal:  Viruses       Date:  2018-09-18       Impact factor: 5.048

Review 10.  Antiviral therapy for respiratory viral infections in immunocompromised patients.

Authors:  Lokesh Shahani; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Expert Rev Anti Infect Ther       Date:  2017-01-16       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.